Colposcopy Market Covering Growth Inclinations & Development Strategies Until 2023

 Market Scenario

A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.

For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.

The upcoming Global Colposcopy Market trends is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.

Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6273 

Company Profiles            

• Carl Zeiss
• Olympus Corporation
• Danaher Corporation
• Philips Healthcare
• CooperSurgical
• McKesson Corporation
• DYSIS Medical
• Atmos
• Alliton
• Seliga Microscopes
• Karl Kaps
• Bovie Medical

Segmentation

The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.

On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.

On the basis of instrument portability, the market is classified into portable, fixed, and handheld.

On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.

On the basis of magnification type, the market is classified into fixed magnification and variable magnification

On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.

The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 

The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.

The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.

Regional Market Summary

Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.

The Americas is likely to dominate the global colposcopy market owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.

Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  

The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/colposcopy-market-6273

Electronic Pill Market Growth Analysis, Industry Trends, And Forecast By 2023

 Market Scenario

Electronic pills are equipped with sensors and cameras which allow capturing of several images of the gastrointestinal tract. They are used for diagnostic purposes and are increasingly replacing traditional diagnostic methods. It further monitors various parameters such as temperature, conductivity, pH, and dissolved oxygen. Market Research Future (MRFR) has thoroughly studied the trends and patterns governing the global electronic pills market over the forecast period of 2018-2023 in a detailed study. MRFR projects a CAGR of 15% within the electronic pills market over the forecast period.

 

Towering prevalence of gastrointestinal disorders has driven the market for electronic pills. Electronic pills alleviate tedious and painful diagnostic procedures such as colonoscopy and endoscopy and provide accurate results without much discomfort to the patient. Surging cases of stomach cancer coupled with increasing preference for minimally invasive medical procedures is likely to augment the growth of the electronic pills market. Healthcare professionals are increasingly adopting theses pills as they facilitate on-site diagnosis. Other factors which contribute to the growth of the market include improving reimbursement scenario and rise in global geriatric population who are more susceptible to various chronic diseases. Additionally, capsule endoscopy has gained widespread adoption as a non-invasive diagnostic method which is likely to fuel the growth of the market over the forecast period with new Electronic Pill Market Technology. On the contrary, the growth of the electronic pills market can be impeded by factors such as lack of awareness, capsule retention, and bowel obstruction. Moreover, high costs aligned with electronic pills and regulatory restrictions are anticipated to hinder the growth of the market.

 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6204

 

Segmentation

The global electronic pill market has been segmented based on application, target area, part, and end user.

 

By application, the electronic pill market has been segmented into capsule endoscopy, drug delivery, and patient monitoring.

 

By target area, the electronic pill market has been segmented into oesophagus, stomach, small intestine, and large intestine.

 

By part, the electronic pill market has been segmented into biocompatible capsule encasing microsensors, control chip, radio transmitter and power source.

 

By end user, the electronic pill market has been segmented into Hospitals, diagnostic centers, clinical research organizations, and medical centers.

 

Regional Analysis

By region, the electronic pill market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

 

In 2017, the global electronic pill market was led by the Americas. The dominance of the Americas market can be attributed to the surging prevalence of gastrointestinal diseases, vigorous R&D activities and fast uptake of the latest technologies in the region.

 

Europe follows the Americas closely and is estimated to showcase substantial growth over the forecast period. Escalating cases of gastric cancer and high demand for diagnostics services is fuelling the growth of the market.

 

The APAC electronic market is likely to witness the fastest growth over the forecast period. The growth of the market can be attributed to increasing patient population, growing medical tourism in the region, and extensive R&D activities and high investment by the governments in the region create a conducive environment for the growth of the market.

 

The MEA market accounts for the least share of the electronic pill market. The growth of the market might be restrained by stringent government policies and poor economic conditions.

 

Competitive Landscape

Medtronic, JINSHAN Science & Technology, Medimetrics (Mexico), Medisafe, CapsoVision, Inc. (US), Given Imaging Ltd. (Israel), (Bio-Images Drug Delivery) BDD LTD (UK), Proteus Digital Health (US), Olympus Corporation, and INTROMEDIC are the distinguished players in the electronic pill market.

 

Industry Updates

February 2019 - a new electronic pill equipped with Wi-Fi transmitter has been developed which is capable of harvesting energy from inside a patient's stomach and record core body temperature and then send data to an external monitor.

 

Browse More Details of the Report @

https://www.marketresearchfuture.com/reports/electronic-pill-market-6204

 

Immunofluorescence Assay Market Global Analysis, Size, Share, Trends, And Forecast 2020 To 2023

 Market Scenario

The growing prevalence of chronic and infectious diseases increase in research and development activities, growing government investments for R&D activities, increased need for rapid and sensitive diagnostics, and adoption of technologically advanced systems are the key factors for the market to grow. However, factors such as, expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.

The Global Immunofluorescence Assays Market Size is expected to reach an approximate CAGR of 5.8% during the forecast period.

According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease.  Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.

However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6177

Key Players

Some of the key players for the global Immunofluorescence Assay market are Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc.,BioTek Instruments,Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc. Becton Dickinson and Company , Merck , Agilent Technologies , TCS Biosciences Ltd, Maxvision Biosciences Inc. and Others.

Segmentation

The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique is sub segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and micro immunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method and double staining method. On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labelling dyes and species type. Instruments is further sub segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.

Regional Market Summary

The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.

It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.

Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.

The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. 

Browse More Report Details @  https://www.marketresearchfuture.com/reports/immunofluorescence-assay-market-6177 

Overactive Bladder Treatment Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2023

 Market Scenario:

Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market analysis during the assessment period.

The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market growth is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.

 

Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6248

Company Profiles    

• Astellas Pharma Inc.
• Pfizer, Inc.
• Teva Pharmaceutical
• Allergan, Plc. 
• Mylan N.V. 
• Endo International Plc 
• Hisamitsu Pharmaceutical Co., Inc.
• Sanofi S. A.
• Aurobindo Pharma Limited 
• Johnson & Johnson
• Intas Pharmaceuticals Ltd. 
• Apotex Inc. 
• Macleods Pharmaceuticals Ltd. 
• Medtronic PLC
• Cogentix Medical, Inc.
• Others

Segmentation

The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.

On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.

The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.

On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.

Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.

The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.

The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.

The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.

Regional Market Summary

The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.

Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.

The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.

The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248

Optical Imaging Market Global Analysis, Size, Share, Trends, And Forecast 2020 To 2023

 Market Scenario

Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market size is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.

Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.

Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.

Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6172

However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.

Segmentation

The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.

On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Market Summary

In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.

Europe is the second largest market and holds a healthy place in global optical imaging market share due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.

Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.

Browse More Report Details @  https://www.marketresearchfuture.com/reports/optical-imaging-market-6172   

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Top Trends In Transthyretin (TTR) Amyloidosis Market 2020 – 2023 By Growth Factors And Industry Players Overview

 Market Scenario

The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6155

Top Market Players

• Alnylam Pharmaceuticals
• Pfizer
• Merck
• Ionis Pharmaceuticals Inc.
• Corino Therapeutics Inc
• Arcturus Therapeutics
• Proclara Bioscience

Market Segmentation                                                                                                                          

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.

Regional Market Summary

Transthyretin Amyloidosis (ATTR) Market share and trends analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.

Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155

Top Trends In Gene Panel Market 2020 – 2023 By Growth Factors And Industry Players Overview

 

Gene Panel Market Overview

A gene panel is a type of test that helps to examine several genes simultaneously for cancer-associated mutations. This test is capable of evaluating a variety of genes that can provide cancer information to provide an accurate diagnosis to help prevent or stop the spread of cancer. 

According to Market Research Future (MRFR), the global gene panel market is projected to cross USD 4.347.32 million with a CAGR of 12.16% by 2018 to 2025 (forecast period). The report is a broad combination of qualitative and quantitative information that illustrates key business developments, issues affecting industry and competition, as well as developments in the gene panel market. 

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/6100

Gene Panel Market Dynamics 

Owing to the rise in the incidence of chronic diseases worldwide, the global market for gene panels is expected to expand significantly. The increase in the number of company initiatives worldwide and the advantages of the gene panels are major factors expected to fuel the market for the gene panel during the forecast period. However, in the coming years, stringent rules and regulations for pharmaceutical companies and health problems related to genetic data are likely to impede the gene panel market. However, ongoing research and development in the field of gene sequencing are expected to pose substantial market growth opportunities during the forecast period. 

Gene Panel Market Segmentation 

The global market gene panel market has been segmented by product & service, technology, design, application, and end-user. 

Based on product & service, the market has been split into test kits and test services. 

Based on the technology, the global market for gene panels has been bifurcated into an amplicon-based approach and a hybridization-based approach. 

Based on the design, the global market for gene panels was divided into pre-designed gene panels and customized gene panels. 

Based on the application, the global market for gene panel was listed as a cancer risk assessment, congenital condition diagnosis, and pharmacogenetics. 

Based on end-user, the market for gene panel was divided into hospitals, diagnostic laboratories, and others. 

Gene Panel Market Regional Analysis 

Region-wise, the global market for gene panel was divided into North America, Europe, the Asia Pacific, and the Middle East & Africa. 

North America is further divided into the United States and Canada. The United States of America is likely to be leading the global demand for gene panels. It can be due to the increasing prevalence of cancer in the region. Almost 1,688,780 new cases were reported in the US in 2017. 

The European gene panel market is expected to be second-largest during the forecast period. The incidence rate for all cancers is expected to increase by 2% in the United Kingdom to 742 cases per 100,000 people between 2014 and 2035. This increasing cancer case, combined with the improved performance of the gene panel, is expected to drive market development. 

Due to the rising expenditure on healthcare and the presence of a broad patient pool, the Asia Pacific market is projected to have a significant growth rate during the forecast period. 

The Middle East & Africa market is expected to grow due to increasing healthcare spending, increasing investment by major market players, and growing patient pools in this region. For example, according to the International Trade Administration, expenditure in the UAE amounted to USD 17 billion in 2017 and is projected to reach USD 21.3 billion by 2021. 

Gene Panel Market Key Players  

The key players in the global gene panel market are Agilent Technologies Inc. (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Illumina Inc. (US), BGI Genomics (China), Integrated DNA Technologies, Inc. (the US), GENEWIZ (US), Novogene Corporation (US), Personalis, Inc. (US), GATC Biotech AG (Germany), ArcherDX, Inc. (the US), GeneDx (Switzerland), and CENTOGENE AG (Germany). 

Gene Panel Industry News

In October 2019, Qiagen and Illumina (US) stated a 15-year agreement to widen the development and use of NGS-based in vitro diagnostic (IVD) kits for patient management and companion diagnostics. This collaboration has become a significant component of Qiagen's NGS strategy, which tends to include universal solutions for use with any sequencer, as well as the GeneReader NGS System for use primarily with smaller, targeted gene panels.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/gene-panel-market-6100

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com